Trial Profile
An Observational Study of BOTOX for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Therapeutic Use
- Acronyms GRACE
- Sponsors Allergan
- 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association
- 22 Nov 2020 Results presented at the 50th Annual Meeting of the International Continence Society
- 22 Nov 2020 Results assessing methodologies used for onabotulinumtoxinA administration for treatment of patients with overactive bladder presented at the 50th Annual Meeting of the International Continence Society